

December 11, 2019

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

**Sub: Disclosure of Related Party Transactions under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards for the half year ended 30th September, 2019.

The said disclosure has also been published on the website of the Company.

This is for your information and record.

Thanking you,

Yours faithfully,  
For Glenmark Pharmaceuticals Limited



**Harish Kuber**  
Company Secretary & Compliance Officer

Encl: As above

Information on significant related party transactions on a consolidated basis as required by Ind AS-24 - 'Related Party Disclosures' are given below:

**Related parties with whom the Group has transacted during the period**

**Key Management Personnel**

Mr. Glenn Saldanha (Chairman & Managing Director)  
 Mrs. Cherylann Pinto (Executive Director)  
 Mr. V S Mani (Executive Director & Global Chief Financial Officer)  
 Mr. Rajesh Desai (Non-executive Director)  
 Mr. Harish Kuber (Company Secretary & Compliance Officer )  
 Mrs. B. E. Saldanha (Non-executive Director)  
 Mr. D.R.Mehta (Non-executive Director)  
 Mr. Bernard Munos (Non-executive Director)  
 Mr. J.F.Ribeiro (Non-executive Director)  
 Dr.Brian W. Tempest (Non-executive Director)  
 Mr. Sridhar Gorthi (Non-executive Director)  
 Mr. Milind Sarwate (Non-executive Director)  
 Ms. Sona Saira Ramasastry (Non-executive Director with effect from 1 April 2019)

**Enterprises over which significant influence exercised by key management personnel/directors**

Glenmark Foundation  
 Glenmark Aquatic Foundation  
 Trilegal

Nature of Transaction	Rs in million
	As at 30 September 2019
<b>Expenditure incurred for CSR activities to</b>	
Glenmark Foundation	65.23
Glenmark Aquatic Foundation	47.15
<b>Transactions with key management personnel</b>	
Remuneration	
- Mrs. Cherylann Pinto	19.11
- Mr V S Mani	30.58
- Mr. Harish Kuber	2.29
Sitting fees paid to Non-executive Directors	4.2
<b>Related party balances</b>	
As at 30 September 2019	
Rs in million	
(Payable)/ Advance given	
Glenmark Foundation	(1.00)

The directors are covered under the Group's gratuity policy and ESOP scheme along with other employees of the Group. Proportionate amount of gratuity and stock compensation expense is not included in the aforementioned disclosures as it cannot be separately ascertained.

